잠시만 기다려 주세요. 로딩중입니다.

Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study

Korean Journal of Family Medicine 2020년 41권 5호 p.339 ~ 345
조용호, 배경현, 이동률, 이정운,
소속 상세정보
조용호 ( Cho Yong-Ho ) - Wonkwang University School of Medicine Wonkwang University Sanbon Hospital Department of Family Medicine
배경현 ( Bae Kyung-Hyun ) - Wonkwang University School of Medicine Wonkwang University Sanbon Hospital Department of Family Medicine
이동률 ( Lee Dong-Ryul ) - Wonkwang University School of Medicine Wonkwang University Sanbon Hospital Department of Family Medicine
이정운 ( Lee Jung-Un ) - Wonkwang University School of Medicine Wonkwang University Sanbon Hospital Department of Family Medicine

Abstract


Background: Intermittent dosing regimens for oral risedronate (once-monthly and once-weekly) were developed for patient convenience. While several studies have reported the anti-fracture efficacy of weekly dosing, few have assessed monthly dosing. The lower efficacy of monthly dosing has been previously suggested. The aim of this study was to compare the anti-fracture efficacy of monthly and weekly dosing.

Methods: We obtained information from the Korea National Health Insurance Service database from 2012 to 2017 of Korean women of ≥50 years of age who used weekly or monthly risedronate. We compared the time of occurrence of the first osteoporotic fracture after the first prescription of risedronate. Using a Cox proportional model, we assessed incidence rate ratios (IRRs) with 95% confidence intervals (CIs) for fractures at any site, and the hip, vertebral, and non-vertebral sites between both regimens. Propensity score weighting was used to balance the treatment groups.

Results: The study populations were distributed according to dosing frequency (monthly, 27,329; weekly, 47,652). There was no significant difference in the incidence rate of new fractures in any site (IRR, 1.008; 95% CI,0.963?1.055; P=0.737), hip (IRR, 0.999; 95% CI, 0.769?1.298; P=0.996), vertebral (IRR, 0.962; 95% CI, 0.890?1.040; P=0.330), or non-vertebral (1.022; 95% CI, 0.968?1.078; P=0.439) sites between monthly and weekly risedronate.

Conclusion: The anti-fracture efficacy at any site and the examined individual sites was similar for the monthly and weekly risedronate regimens. Large-scale randomized controlled trials are required for confirmation.

키워드

Bisphosphonate; Risedronic Acid; Osteoporosis; Fracture

원문 및 링크아웃 정보

등재저널 정보

KCI